EGF Theramed Health (AUH) Price & Analysis

0 Followers

AUH Stock Chart & Stats

€0.06

<€0.01(1.43%)

At close: Jan 08 4:00 PM EST

€0.06

<€0.01(1.43%)

Day’s Range― - ―

52-Week Range€0.02 - €0.15

Previous CloseN/A

Volume0.00

Average Volume (3M)44.00

Market Cap

€502.50K

Enterprise Value€2.54M

Total Cash (Recent Filing)€10.47K

Total Debt (Recent Filing)€1.63M

Price to Earnings (P/E)―

Beta-1.56

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding11,616,665

10 Day Avg. Volume120

30 Day Avg. Volume44

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.26

Price to Sales (P/S)0.00

P/FCF Ratio38.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving Cash GenerationThe shift to slightly positive operating and free cash flow in 2025 signals emerging cash generation after several years of negative flows. Although the amount is small, sustained positive cash flow would reduce near-term financing needs and provide a foundation for incremental investment or product commercialization.

Reduced Net Loss TrendA multi-year reduction in net losses from the 2020 peak indicates the company has narrowed its operating deficit. Persistent improvement in loss magnitude reflects progress toward operational stabilization, which is necessary for eventual profitability once revenue generation or scaling initiatives commence.

Cost Discipline SignalThe documented improvement in cash flow implies management enacted cost controls or restructuring to conserve cash. Effective and durable cost discipline can extend runway, lower dilution risk from future financings, and allow more time to pursue product development or market entry strategies.

Bears Say

No Reported RevenueZero reported revenue across the available periods shows the company lacks commercialized products or monetization. Without recurring revenue, long-term viability depends on successful product launches or continual external funding, substantially increasing execution and dilution risk for stakeholders.

Negative Shareholders' EquityNegative equity combined with a tiny asset base and meaningful debt denotes structural solvency pressure. This severely limits financial flexibility, raises the probability of recapitalization or dilution, and constrains the firm's ability to invest in growth or withstand protracted development timelines.

Persistent Operating LossesOngoing negative EBIT/EBITDA and a larger 2025 loss indicate the business has not achieved operating leverage or profitability. Continued operating deficits will deplete cash reserves absent material revenue growth or fresh capital, weakening competitive position and limiting R&D or commercialization capacity.

EGF Theramed Health News

EGF Theramed refreshes board and finance leadership

EGF Theramed Health ( ($TSE:TMED) ) has shared an announcement. EGF Theramed Health Corp. has appointed Lin Ye...

5M ago

AUH FAQ

What was EGF Theramed Health’s price range in the past 12 months?

EGF Theramed Health lowest stock price was €0.02 and its highest was €0.15 in the past 12 months.

What is EGF Theramed Health’s market cap?

EGF Theramed Health’s market cap is €502.50K.

When is EGF Theramed Health’s upcoming earnings report date?

EGF Theramed Health’s upcoming earnings report date is Nov 03, 2026 which is in 92 days.

How were EGF Theramed Health’s earnings last quarter?

EGF Theramed Health released its earnings results on Jun 01, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.006.

Is EGF Theramed Health overvalued?

According to Wall Street analysts EGF Theramed Health’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does EGF Theramed Health pay dividends?

EGF Theramed Health does not currently pay dividends.

What is EGF Theramed Health’s EPS estimate?

EGF Theramed Health’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does EGF Theramed Health have?

EGF Theramed Health has 11,616,665 shares outstanding.

What happened to EGF Theramed Health’s price movement after its last earnings report?

EGF Theramed Health reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of EGF Theramed Health?

Currently, no hedge funds are holding shares in DE:AUH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

EGF Theramed Health

EGF Theramed Health Corp. focuses on providing psychedelic-based therapies to address various mental health challenges. The company's products are specifically utilized in the treatment of conditions such as intractable depression, anxiety disorders, post-traumatic stress disorder (PTSD), and general depression. Established in 2011, this firm operates from its main headquarters in Vancouver, Canada.